RNAi screening of the kinome with cytarabine in leukemias

Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

(2017) J. H. M. Schellens et al.   JOURNAL OF CLINICAL ONCOLOGY

High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation

(2010) David O Azorsa et al.   BMC GENOMICS

Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years

(2010) Hagop Kantarjian et al.   CANCER

RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells

(2010) Shilpi Arora et al.   GYNECOLOGIC ONCOLOGY

RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma

(2010) Shilpi Arora et al.   Molecular Cancer

Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy

(2009) C. Cavelier et al.   CANCER RESEARCH

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

(2009) Claudia Scholl et al.   CELL

Phase II Study of Thalidomide Plus Dexamethasone Induction Followed by Tandem Melphalan-Based Autotransplantation and Thalidomide-Plus-Prednisone Maintenance for Untreated Multiple Myeloma: A Southwest Oncology Group Trial (S0204)

(2009) Mohamad A. Hussein et al.   JOURNAL OF CLINICAL ONCOLOGY

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

(2009) David O Azorsa et al.   Journal of Translational Medicine

NEK11 regulates CDC25A degradation and the IR-induced G2/M checkpoint

(2009) Marina Melixetian et al.   NATURE CELL BIOLOGY

Statistical methods for analysis of high-throughput RNA interference screens

(2009) Amanda Birmingham et al.   NATURE METHODS

Anthracycline Dose Intensification in Acute Myeloid Leukemia

(2009) Hugo F. Fernandez et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optimal induction and post-remission therapy for AML in first remission

(2009) J. M. Rowe   Hematology-American Society of Hematology Education Program

High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival

(2008) D. T. Starczynowski et al.   BLOOD

Genomic instability in myeloid malignancies: Increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair

(2008) Annahita Sallmyr et al.   CANCER LETTERS

Acute Myeloid Leukemia; Decided Victories, Disappointments, and Detente: An Historical Perspective

(2008) M. S. Tallman   Hematology-American Society of Hematology Education Program

Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia

(2008) T. Haferlach   Hematology-American Society of Hematology Education Program